SREBF2 and ovarian carcinoma: Additionally, ovarian cancer mutant cells/SREBF2-KD (SREBF2 disrupted using CRISPR technology) treated with paclitaxel in low, but not high serum or in presence of statin showed a significantly lower cell viability [130].